Stress Management Toolkit for People Living With Dementia and Their Care Partners

Dementia Clinical Trial

Official title:

Development of a Dyadic Stress Management Toolkit for People Living With Dementia and Their Care Partners

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05465551
• Other study ID #: Pro00110944
• Secondary ID: P30AG072958
• Status: Recruiting
• Phase: Early Phase 1
• Start date: December 20, 2022
• Est. completion date: July 30, 2025

Study information

• Verified date: June 2024
• Source: Duke University
• Contact: Melissa L Harris, PhD
• Phone: 4055131271
• Email: Melissa.L.Harris[@]Duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to develop a prototype of a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home.

A human-centered design approach will be used to develop and user-test a prototype of a dyadic, tangible stress-management toolkit with and for PLWD and their care partners; and to explore the feasibility of collecting several stress-related outcomes. A total of 4 focus groups (n=3-4 dyads/group) will be convened to explore the experiences, perceptions, preferences, and recommendations of dementia-caring dyads regarding stress, stress management, and key components and features of a stress management toolkit. Eligible tools for the toolkit include low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. Ten dyads who were not involved in prototype development will then use the toolkit for 2 weeks. Feedback on usability, feasibility, and acceptability will be collected through questionnaires (end of weeks 1 and 2) and 3 focus groups (3-4 dyads/group at end of week 2). We will collect stress-related, participant-reported outcomes (e.g., neuropsychiatric symptoms of dementia, caregiver stress, dyadic relationship strain), and saliva biospecimens from participants with dementia and their care partners at baseline and end of week 2, to explore their utility as endpoints in a future toolkit intervention that uses a single-arm, pre-post study design. Results will yield valuable data to support development and preliminary testing of a stress management toolkit intervention in a future pilot study.

This study involves human subjects and is expected to yield no more than minimal risk. Tools eligible for the toolkit must have demonstrated high degrees of safety in prior research. Major risks for participation include the potential for negative emotional responses to focus group discussions and surveys pertaining to stress, excess time burden to participate in the study, and breach of confidentiality. It is not anticipated, but there is a potential for physical discomfort if tools are not used as directed, which is why the toolkits will include a user guide outlining safety information, which a research team member will review with each participant prior to use.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: July 30, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion criteria for participants with dementia are:

• age 60 years and over with a diagnosis of dementia of any type

• able to express self verbally

• English speaking.

Exclusion criteria for participants with dementia is:

• has a hearing or visual impairment that limits their ability to participate in the screening process or to participate in a focus group.

Inclusion criteria for care partner participants are:

• age 21 years and older

• identify as a primary care partner of someone with dementia

• English speaking

Exclusion criteria for care partner participants is:

• has a hearing or visual impairment that limits their ability to participate in the screening process or to participate in a focus group.

Dyadic eligibility criteria include:

• both the PLWD and care partner reside in the same household or personal residence in the community

• dyad has lived together for at least 1 month

• dyad has telephone or internet access

• Dyads will be excluded if they reside in assisted living or other long-term care setting.

Dyads participating in user-testing phase will also be excluded if either member:

• currently receives cytokine-based therapy

• currently receives radiation therapy to the salivary glands or thyroid

• are diagnosed with Cushing or Addison's disease

Related Conditions & MeSH terms

• Caregiver Burden
• Dementia
• Stress

Intervention

Combination Product:
• Stress Management Toolkit
The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.

Locations

Country	Name	City	State
United States	Caregiver and dementia community support organizations	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of toolkit use	Number of days toolkit was used over the last week (range 0-7) will be assessed among participants enrolled in user-testing arm.	End of week 1 of user-testing period
Primary	Frequency of toolkit use	Number of days toolkit was used over the last week (range 0-7) will be assessed among participants enrolled in user-testing arm.	End of week 2 of user-testing period
Primary	Enrollment rate	Percentage of participant dyads enrolled/dyads screened in user-testing arm.	Through study completion, an average of 1 year
Primary	Withdrawal rate	Percentage of dyads that withdraw/dyads enrolled in user-testing arm.	Through study completion, an average of 1 year
Primary	Frequency of adverse events and injuries	Number of adverse events and injuries reported in user-testing arm.	Through study completion, an average of 1 year
Primary	Participant satisfaction with toolkit, as assessed using a toolkit satisfaction scale	Investigator developed multi-item satisfaction scale will include Likert-scaled items pertaining to satisfaction with design and delivery of the toolkit among participants in the user-testing arm; item ranges 1=not satisfied at all to 5 very satisfied). Scores will be averaged to yield and overall satisfaction score with higher scores indicating a greater degree of satisfaction.	Within 1 week after user-testing period
Primary	Participant perceived benefit with toolkit, as assessed using a toolkit benefit scale	Investigator developed multi-item benefit scale will include Likert-scaled items pertaining to perceived benefit from the toolkit among participants in the user-testing arm; item ranges 1=not beneficial at all to 5 very beneficial). Scores will be averaged to yield and overall benefit score with higher scores indicating a greater degree of benefit.	Within 1 week after user-testing period
Secondary	Percentage of participant completion of neuropsychiatric symptoms of dementia outcome measure, as assessed using the Neuropsychiatric Inventory-Questionnaire	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). NPI assesses severity (1=mild, 2=moderate, 3=severe) and caregiver distress (range 0=not distressing at all to 5 extreme or very severe) of 12 domains of neuropsychiatric symptoms of dementia. Higher scores indicate more severe or distressing symptoms.	Baseline, pre user-testing period
Secondary	Percentage of participant completion of neuropsychiatric symptoms of dementia outcome measure, as assessed using the Neuropsychiatric Inventory-Questionnaire	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). NPI assesses severity (1=mild, 2=moderate, 3=severe) and caregiver distress (range 0=not distressing at all to 5 extreme or very severe) of 12 domains of neuropsychiatric symptoms of dementia. Higher scores indicate more severe or distressing symptoms.	Within 1 week after user-testing period
Secondary	Percentage of participant completion of caregiver stress outcome measure, as assessed using the Perceived Stress Scale	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). The Perceived Stress Scale is a 10-item measure that assesses recent stress-related thoughts and feelings on 5-point scale with higher scores indicating higher levels of stress.	Baseline, pre user-testing period
Secondary	Percentage of participant completion of caregiver stress outcome measure, as assessed using the Perceived Stress Scale	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). The Perceived Stress Scale is a 10-item measure that assesses recent stress-related thoughts and feelings on 5-point scale with higher scores indicating higher levels of stress.	Within 1 week after user-testing period
Secondary	Percentage of participant completion of dyadic relationship strain outcome measure, as assessed using the Dyadic Relationship Scale	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at baseline/total number of participants enrolled in user-testing arm). The Dyadic Relationship Scale includes a care recipient 10-item version and care partner specific 11-item version. Both scales measure dyadic strain and positive dyadic interaction. Total scores range from 0-30 for the care recipient version, and 0-33 for care partner specific, with higher scores indicative of higher levels of dyadic strain.	Baseline, pre user-testing period
Secondary	Percentage of participant completion of dyadic relationship strain outcome measure, as assessed using the Dyadic Relationship Scale	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Number of participants who complete the measure at post user-testing/total number of participants enrolled in user-testing arm). The Dyadic Relationship Scale includes a care recipient 10-item version and care partner specific 11-item version. Both scales measure dyadic strain and positive dyadic interaction. Total scores range from 0-30 for the care recipient version, and 0-33 for care partner specific, with higher scores indicative of higher levels of dyadic strain.	Within 1 week after user-testing period
Secondary	Percentage of participant completion of physiologic stress outcome measure, as assessed through salivary cortisol biospecimens	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Total number of biospecimen samples collected among participants at baseline/total number of participants enrolled in user-testing arm*5).; Salivary cortisol biospecimens will be collected using salivary sample kits sent to participants' homes by mail. Participants with dementia and care partners will each be asked to collect 5 samples at baseline and will collect samples themselves in their own homes with guidance and support from research team. Samples will be mailed back to research team using preaddressed, prestamped envelopes.	Baseline, pre user-testing period
Secondary	Percentage of participant completion of physiologic stress outcome measure, as assessed through salivary cortisol biospecimens	Percentage of participant completion for this measure will be calculated for participants enrolled in the user-testing arm (Total number of biospecimen samples collected among participants at post user-testing/total number of participants enrolled in user-testing arm*5).; Salivary cortisol biospecimens will be collected using salivary sample kits sent to participants' homes by mail. Participants with dementia and care partners will each be asked to collect 5 samples at post user-testing and will collect samples themselves in their own homes with guidance and support from research team. Samples will be mailed back to research team using preaddressed, prestamped envelopes.	Within 1 week after user-testing period